Management of hypertension and heart failure in patients with Addison's disease

Area of Science:

• Endocrinology
• Cardiology
• Nephrology

Background:

• Addison's disease, or primary adrenal insufficiency, necessitates glucocorticoid and mineralocorticoid replacement therapy.
• Hypertension and heart failure are potential complications of Addison's disease, impacting management strategies.
• The renin-angiotensin-aldosterone system plays a critical role in regulating blood pressure and fluid balance, and its function is altered in Addison's disease.

Observation:

• Optimizing glucocorticoid replacement is the initial step in managing both hypertension and heart failure in Addison's disease.
• Excessive glucocorticoid doses may contribute to hypertension, necessitating dose reduction.
• Mineralocorticoid excess, indicated by clinical or biochemical signs, warrants fludrocortisone dose reduction in hypertensive patients.

Findings:

• For persistent hypertension in Addison's disease without mineralocorticoid excess, angiotensin II receptor antagonists or ACE inhibitors are recommended, with stable fludrocortisone doses.
• Dihydropyridine calcium channel blockers serve as second-line agents for hypertension, while diuretics should be avoided.
• In heart failure, reduced fludrocortisone dosage is typically indicated due to increased total body sodium and water; loop diuretics are appropriate, but aldosterone antagonists are contraindicated.

Implications:

• Tailored management of hypertension and heart failure in Addison's disease is crucial for patient outcomes.
• Understanding the interplay between the renin-angiotensin-aldosterone axis and Addison's disease guides therapeutic decisions.
• Further research into optimizing hormonal replacement and cardiovascular management in Addison's disease is warranted.